跳至主要内容
临床试验/NCT01188330
NCT01188330Unknown不适用

Randomized Study Comparing the Interest of a Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival of Elderly Patients With Acute Myeloid Leukaemia. MLSP/IPC 2009-003

Institut Paoli-Calmettes3 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2010年3月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
3
主要终点
functional status

研究概览

简要总结

Acute myeloid leukaemia (AML) is a disease of the elderly, with a median age at diagnosis of 65. A poor outcome in this population has been well established, with very short overall survival (OS) and disease free survival (DFS).There are numerous bad prognostic factors related to the disease itself or to the patient's medical condition.

This study will evaluate the impact of a Comprehensive Geriatric assessment (CGA) performed at diagnosis with planned interventions according to disabilities and monthly follow-up by a nurse practitioner during 6 months on functional status of older cancer patients treated for Acute myeloid leukaemia. Functional status will be assessed with the Lawson Instrumental Activities of Daily Living (IADL) scale at diagnosis and 6 months after randomisation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
70 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 70 years and older
  • Referred for treatment following a diagnosis of acute myeloid leukaemia.
  • signed informed consent

排除标准

  • Terminal patients, with a life expectancy estimated to be less than 3 months, will be excluded from the study, due to ethical issues and the fact that they are unlikely to benefit from this evaluation.
  • Patients unable to give informed consent.

结局指标

主要结局

functional status

时间窗: 6 months

The functional status is evaluated with KATZ INDEX : BASIC ACTIVITIES OF DAILY LIVING (ADL) and Older American Resources and Services, Instrumental Activities of Daily Living (IADL) mesured at diagnosis and 6 month after inclusion.

次要结局

  • nutritional status(6 months)
  • survival(6 months)
  • quality of life(6 months)

研究者

发起方
Institut Paoli-Calmettes
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

终止
3 期
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AMLLeukemia, MyeloidAcute Myeloid Leukemia (AML)Leukemia
NCT00568633Stanford University58
进行中(未招募)
1 期
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2013-002730-21-GBCardiff University2,000
进行中(未招募)
1 期
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2013-002730-21-DKCardiff University2,000
Unknown
2 期
Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML PatientsAcute Myeloid Leukemia
NCT03045627Shandong University120
Unknown
2 期
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsAcute Myeloid LeukaemiaMyelodysplastic Syndrome
NCT02272478Cardiff University1,600